Nursing Data Help Predict Cirrhosis Patient's Survival
“Liver specialists currently use blood tests to assess risk, and while these are powerful tools, they only capture a small portion of the patient’s risk. There’s a sense that there are things outside of those blood tests that are meaningful,” says lead author Elliot Tapper, MD, Clinical Fellow in Gastroenterology and Hepatology at BIDMC and Harvard Medical School. “We hypothesised that frailty, or decreased functional reserve, may be one of those factors, and it turns out that our nurses have been calculating that frailty all along, and we just haven’t noticed.”
Dr. Tapper and colleagues analysed data from 734 patients admitted a collective 1,348 times to BIDMC’s liver unit between 2010 and 2013. They had access to the patients’ MELD (model for end-stage liver disease) scores, an algorithm based on blood tests that is used for transplant planning. The higher the MELD score, the more likely the patient will die without a liver transplant.
In addition, the research team had access to data collected by nurses and used for general care of the patients but not specifically related to liver disease, including assessments used to determine a patient’s risk for skin ulcers or whether the patient needs help transferring out of bed or getting to the bathroom.
As Dr. Tapper notes, “These data points help determine a patient’s level of frailty and inform very important nursing activities, but until now no one has actually looked at whether those metrics speak to a patient’s overall risk.”
After combining traditional assessment tools like MELD with the data from the nurses’ assessments, the researchers were able to predict the 90-day mortality rate with 83 percent accuracy and the rate at which patients were discharged to a rehabilitation facility at 85 percent accuracy.
“This is a very significant improvement in our power to provide prognosis, be it 90-day survival, discharge to a rehabilitation hospital or length of stay in the hospital based on a simple inexpensive clinical tool that is readily available in all hospitals across the country,” according to senior author Michelle Lai, MD, MPH, a liver specialist in the Division of Gastroenterology and Hepatology at BIDMC and Assistant Professor of Medicine at Harvard Medical School.
In harnessing the information in the nursing assessments, the research team has landed on something that can be acted on.
“Many of the things identified in the nursing assessments are modifiable,” Dr. Tapper explains. “By intensifying their nutritional support, utilising physical therapy, by identifying the patients who will benefit from rehabilitation, we may be able to improve their frailty and therefore their ability to survive, for example, the liver transplant or at least to stay healthier after discharge, at home and away from the hospital.”
Source: Beth Israel Deaconess Medical Center
Image Credit: Wikimedia Commons
Published on : Sat, 11 Apr 2015
Print as PDF
The iLA Membrane Ventilator is an extrapulmonary ventilation system which is used primarily to remove carbon dioxide. The heart pumps blood through it as it does through a natural organ. The gas exchange takes place via a plasma-tight, heparin-coated...
The HAMILTON-C3 ventilator is a modular high-end ventilation solution for all patient groups. Offering a number of unique features, the HAMILTON-C3 is one of the first ventilators featuring the “Ventilation Autopilot” INTELLiVENT-ASV®. The HAMILTON-C3’s...
Get an complete overview of your POCT setup - from one dashboard Your point-of-care-testing setup probably involves many different types of devices from various manufacturers. Radiometer's AQURE point-of-care management system can give you an overview...
The technical and clinical reference standard for all B·R·A·H·M·S PCT assays. All clinical cut-offs and algorithms were developed based on B·R·A·H·M·S PCT sensitive KRYPTOR. Homogeneous immunoassay for the quantitative d
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...